Mustang Bio, Inc.

Overview

"How the company got here" "Mustang Bio was founded in 2015 with the goal of turning promising medical research into potential cures for serious diseases, particularly cancers. The company's strategy involves licensing or acquiring rights to these medical breakthroughs, funding their development, and then either partnering with other companies to bring them to market or developing them itself. Early on, Mustang Bio focused primarily on cancer therapies. A significant expansion of its focus occurred after it licensed a gene therapy for X-linked severe combined immunodeficiency (X-SCID), a rare genetic disorder, from St. Jude Children's Research Hospital. This move broadened the company's pipeline to include treatments for immunodeficiency diseases in addition to cancer. In 2019, the company raised $32 million to support the continued development of its product candidates for blood cancers, solid tumors, and rare genetic diseases." "What it actually does" "Mustang Bio is a biopharmaceutical company that works on developing advanced medical treatments, specifically cell and gene therapies. These therapies are designed to potentially cure difficult-to-treat diseases, with a current focus on various types of cancer and rare genetic disorders. The company partners with leading medical institutions to advance the development of these innovative treatments. Mustang Bio's approach involves identifying promising medical breakthroughs, securing the rights to them, funding the necessary research and development, and then working to bring these potential cures to patients." "CAR T Cell Therapies for Hematologic Cancers" "Mustang Bio is developing CAR T cell therapies, which are a type of immunotherapy (treatment that uses the body's own immune system to fight disease). Specifically, they are working on MB-106, a therapy designed to target CD20, a protein found on certain cancer cells. This treatment is intended for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL), which are types of blood cancers. The company is conducting clinical trials for MB-106 and has reported positive early results, including instances of complete remission in patients." "CAR T Cell Therapies for Solid Tumors" "Mustang Bio is also exploring CAR T cell therapies for solid tumors, which are cancers that form lumps or masses. One of their key programs in this area is MB-101, a therapy targeting a protein called IL13Rα2, which is found on glioblastoma (a type of aggressive brain cancer). They are also developing MB-108, which is an oncolytic virus (a virus engineered to specifically infect and kill cancer cells while sparing healthy ones). Furthermore, Mustang Bio is investigating a combination therapy, MB-109, which combines their CAR T cell therapy (MB-101) with the oncolytic virus (MB-108) to potentially enhance the treatment's effectiveness against brain tumors." "Gene Therapies for Rare Genetic Diseases" "In addition to cancer treatments, Mustang Bio is developing gene therapies for rare genetic diseases. A notable area of focus is X-linked severe combined immunodeficiency (X-SCID), often referred to as 'bubble boy disease,' a serious inherited condition that severely weakens the immune system. The company has licensed a gene therapy for X-SCID and has seen positive results in early trials involving infants." "What management is betting on now" "Mustang Bio's current strategy is to focus its resources on advancing its most promising therapeutic candidates. This includes prioritizing the development of MB-106, their CD20-targeted CAR T cell therapy for blood cancers, and their glioblastoma (GBM) programs, such as MB-101, MB-108, and the combination therapy MB-109. The company is also investing in an 'in vivo' CAR T platform technology, which aims to deliver CAR T therapies directly into the body rather than manufacturing them outside the body. By concentrating on these key areas, Mustang Bio aims to achieve significant data readouts from ongoing clinical trials and move these potential cures closer to market."